Retatrutide Shows 24.2% Weight Loss But Won't Be Available Until 2028

Retatrutide hit **24.2%** weight loss at 48 weeks in Phase 2 trials. That beats tirzepatide's top numbers. But it's still years from your pharmacy shelf, and there's no head-to-head data yet to confirm it actually outperforms existing drugs in practice.

Here's where retatrutide stands in March 2026, and why you probably shouldn't wait for it.

how the triple mechanism works

Retatrutide hits three targets instead of tirzepatide's two. GLP-1 slows stomach emptying and kills appetite. GIP improves insulin sensitivity and helps burn fat. Glucagon cranks up energy expenditure and torches stored fat.

Think of it as adding a turbo engine to an already powerful car. GLP-1 and GIP handle the basics, glucagon provides extra metabolic firepower.

the phase 2 numbers

The trial ran 48 weeks with 12mg weekly doses. Participants lost an average of **24.2%** of their starting weight. For comparison, tirzepatide tops out around 22.5% in similar studies.

But here's the catch: this wasn't a head-to-head trial. Different patients, different protocols, different everything. Comparing across studies is useful but not definitive.

where the research stands now

Phase 2 is done. Phase 3 trials are recruiting patients. FDA submission won't happen until late 2027 at the earliest. Commercial availability is projected for 2028-2029, assuming everything goes perfectly.

That's a long time to wait when tirzepatide and semaglutide are working for people right now.

liver benefits beyond weight loss

New research shows retatrutide reduces liver fat and inflammation markers. (PMID: 41823054) The glucagon pathway specifically targets hepatic fat oxidation, which could help people with fatty liver disease.

Tirzepatide also improves liver health, but retatrutide might have an edge here thanks to the glucagon component. Still early data though.

what we don't know yet

Safety beyond 48 weeks is unclear. The glucagon pathway is new territory for chronic use. Long-term effects on the heart, pancreas, and liver need more study.

Side effect profiles aren't fully mapped either. Phase 2 showed standard GI issues (nausea, vomiting) but with small patient numbers. Rare problems won't show up until larger trials run.

Dosing is also more complex. It starts at 1mg and titrates up to 12mg over months. That's a longer ramp-up than current options.

pricing reality check

Expect retatrutide to cost significantly more than tirzepatide when it launches. Estimates put monthly costs at $2,000-3,000 or higher. Insurance will require you to fail on cheaper options first.

Compounded versions are unlikely. Triple-agonist synthesis is way more complex than current peptides. Most compounding pharmacies couldn't handle it even if regulations allowed it.

should you wait for it

No. Don't put off treatment for 2-3 years hoping for a marginally better drug. Tirzepatide and semaglutide deliver proven results now.

If you're already on tirzepatide and losing well, there's no reason to switch when retatrutide becomes available. If you've plateaued or can't tolerate current options, then it becomes interesting.

The difference between 22.5% and 24.2% weight loss might not justify waiting years and paying significantly more. Bird in hand versus two in the bush.

clinical trial access

Phase 3 trials are actively recruiting. If you qualify and want to try retatrutide now, clinical trials are your only option. Check ClinicalTrials.gov for locations near you.

Keep in mind you might get placebo. And trial protocols are stricter than real-world treatment. But it's the only current path to access.

Most trials require you to be treatment-naive or have failed previous weight loss attempts. Each site has specific eligibility criteria.

the big picture

Retatrutide looks promising. The 24.2% weight loss number is impressive. But it's still experimental medicine with unknown long-term effects and a high projected price tag.

Current drugs work well for most people. Don't delay effective treatment chasing perfect treatment. When retatrutide launches in 2028-2029, you can reassess based on actual data and your results with existing options.

For more on current alternatives, see our guides on tirzepatide and semaglutide.